CAR-T Therapy with Cartesian Therapuetics

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, Dr. Miljković will describe Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG) and the ongoing clinical trial.
Dr. Miljković is the company’s Chief Medical Officer. He is board-certified in hematology, medical oncology, and internal medicine. Prior to joining Cartesian, he was at the National Cancer Institute for over seven years, where as Staff Clinician he specialized in early-stage trials in immuno-oncology. Dr. Miljković has served as Principal Investigator on 6 clinical trials of immunotherapy and targeted agents and as Associate Investigator on more than 20 others. He completed residency at the Johns Hopkins University and Sinai Hospital of Baltimore program in internal medicine, followed by clinical and research fellowships in the joint NCI/NHLBI program at the NIH, where he also served as Chief Fellow."